Effects of itopride hydrochloride and ranitidine in patients with functional dyspepsia: Comparison between prokinetic and acid suppression therapies

Hepato-Gastroenterology

Volumn 54, Issue 78, 2007, Pages 1878-1881

  Chiba, Toshimi ^a   Tokunaga, Yumi ^a   Ikeda, Keisei ^a   Takagi, Ryo ^a   Chishima, Raita ^a   Terui, Torahiko ^a   Kudara, Norihiko ^a   Endo, Masaki ^a   Inomata, Masaaki ^a   Orii, Seishi ^a   Suzuki, Kazuyuki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Functional dyspepsia; Itopride hydrochloride; Ranitidine

Indexed keywords

ITOPRIDE; RANITIDINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DYSPEPSIA; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; QUALITY OF LIFE;

ADULT; AGED; ANTI-ULCER AGENTS; BENZAMIDES; BENZYL COMPOUNDS; DYSPEPSIA; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; KINETICS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RANITIDINE; TREATMENT OUTCOME;

EID: 35948944975     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Tally N, Stanghellini V, Heading RC, et al: Functional gastroduodenal disorders. Gut 1999; 45(Suppl 2):II37-II42.
2. Tack J, Bisschops R, Sarnelli G, et al: Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004; 127:1239-1255.
3. Schlemper RM, van der Werf SD, Vandebrouke JP, et al: Peptic ulcer, non-ulcer dyspepsia and irritable bowel syndrome in The Netherlands and Japan. Scand J Gastroenterol 1993; 200(Suppl):33-41.
4. Olden KW: Brain-gut interactions. West J of Med 1994; 160:55.
5. Revicki DA, Wood M, Wiklund I Crawley J: Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease. Qual Life Res 1998; 7:75-83.
6. Svedlund J, Sjodin I, Dotevall G: GSRS-a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988; 33:129-134.
7. Kawakami H, Hongo M, Okuno Y, et al: Personality deviation and gastric motility in patients with functional dyspepsia. J Clin Gastroenterol 1995; 21(Suppl 1):S179-S184.
8. Quartero AO, de Wit NJ, Lodder AC, et al: Disturbed solid-phase gastric emptying in functional dyspepsia: a meta-analysis. Dig Dis Sci 1998; 43:2028-2033.
9. Hausken T, Berstad A: Wide gastric antrum in patients with non-ulcer dyspepsia. Effect of cisapride. Scand J Gastroenterol 1992; 27:427-432.
10. Geldof H, von der Schee EJ, van Blankenstein M, et al: Electrogastrographic (EGG) study of gastric myoelectrical activity in patients with unexplained nausea and vomiting. Gut 1986; 27:799-808.
11. Lin Z, Eaker EY, Sarosiek I, et al: Gastric myoelectrical activity and gastric emptying in patients with functional dyspepsia. Am J Gastroenterol 1999; 94:2384-2389.
12. Waldron B, Cullen PT, Kumar R, et al: Evidence for hypomotility in non-ulcer dyspepsia: a prospective multifactorial study. Gut 1991; 32:246-251.
13. David D, Mertz H, Fefer L, et al: Sleep and duodenal motor activity in patients with severe non-ulcer dyspepsia. Gut 1994; 35:916-925.
14. Allescher HD, Bockenhoff A, Knapp G, et al: Treatment of non-ulcer dyspepsia: a meta-analysis of placebo-controlled prospective studies. Scand J Gastroenterol 2001; 36:934-941.
15. Farup PG, Watterhus S, Osnes M, et al: Ranitidine effectively relieves symptoms in a subset of patients with functional dyspepsia. Scand J Gastroenterol 1997; 32:755-759.
16. Mones J, Adan A, Segu JL, et al: Quality of life in functional dyspepsia. Dig Dis Sci 2002; 47:20-26.
17. Shenoy KT, Veenasree, Leena KB: Efficacy and tolerability of itopride hydrochloride in patients with non-ulcer dyspepsia. J Indian Med Assoc 2003; 101:387-388.
18. Myung-Gyu Choi, Kyo Young Choo, Byung Wook Kim, et al: The effect of itopride on proximal gastric tone and visceral perception in healthy human. Kor J Gastroenterol 2000; 36:293-301.
19. Predstone HA, Barrowman N, Veldhuyzen van Zanten JO, et al: H2-receptor antagonists in the treatment of functional (nonulcer) dyspepsia: a meta-analysis of randomized controlled clinical trials. Aliment Pharmacol Ther 2001; 15:1291-1299.
20. Myren J, Osnes M, Larsen S, et al: Gastric motility following peroral administration of ranitidine. Scand J Gastroenterol 1984; 19:21-24.
21. Iwanaga Y, Miyashita N, Morikawa K, et al: A novel water soluble dopamine-2 antagonist with anticholinesterase activity in gastrointestinal motor activity. Gastroenterology 1990; 99:57-64.
22. Iwanaga Y, Suzuki N, Kato KI, et al: Stimulatory effects of HSR-803 on ileal motor activity. Jpn J Pharmacol 1993; 62:395-401.
23. Moayyedi P, Soo S, Deeks J, et al: Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. issue 1 CD001960, 2003.
24. Mearin F, Cucala M, Azpiroz F, et al: The origin of symptoms on the brain-gut axis in functional dyspepsia. Gastroenterology 1991; 101:999-1006.
25. Tack J, Piessevaux H, Coulie B, et al: Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998; 115:1346-1352.
26. Tally NJ, Van Zanten SV, Saez LR, et al: A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. Aliment Pharmacol Ther 2001; 15:525-537.
27. Bortolotti M, Coccia G, Grossi G: Red pepper and functional dyspepsia. N Eng J Med 2002; 346:947-948.
28. Riviere PJ: Peripheral kappa-opioid agonists for visceral pain. Br J Pharmacol 2004; 141:1331-1334.
29. Jocic M, Schuligoi R, Schoninkle E, et al: Cooperation of NMDA and tachykinin NK(1) and NK(2) receptors in the medullary transmission of vagal afferent input from the acid-threatened rat stomach. Pain 2001; 89:147-157.